Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of rhuMAb Beta7 in Moderate to Severe Ulcerative Colitis
2011-003409-36Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Etrolizumab in autoimmune colitis, sponsored by Genentech. Started Nov 2011; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-003409-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003409-36.